We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

AMS BIOTECHNOLOGY (EUROPE)

AMS Biotechnology (Europe) Ltd. provides cutting-edge life science technology, products and services for research and... read more Featured Products: More products

Download Mobile App




New ELISA Kit Measures Drug-Induced DNA Breaks

By LabMedica International staff writers
Posted on 07 Sep 2014
Print article
Image: H2AX foci following gamma irradiation for measurement of DNA (Photo courtesy of the [US] National Institutes of Health).
Image: H2AX foci following gamma irradiation for measurement of DNA (Photo courtesy of the [US] National Institutes of Health).
A gamma H2AX pharmacodynamic assay kit for the study of double strand DNA breaks through the detection of the phosphorylated histone, gamma-H2AX, is now available for drug developers as well as biotech and other life science researchers.

The ubiquitous histone H2AX is a 14-kDa member of the H2A histone family that contains an evolutionarily conserved SQ motif at the C-terminus in eukaryotes.

Serine 139 within this motif becomes rapidly phosphorylated by kinases to yield a form known as gamma-H2AX in response to double-strand DNA damage and apoptosis.

There are over 21 anticancer drugs that are known to result in gamma-H2AX formation. As a result, gamma-H2AX is an ideal marker to measure molecular responses to a large number of drugs. While many of these drugs have already received regulatory approval, and are currently being used to manage various types of cancers, they are the subject of ongoing clinical studies to evaluate their efficacy when used alone or in combination with molecularly targeted drugs.

While methods such as Western blots and immunohistochemistry are widely used to detect gamma-H2AX, results are difficult to validate to regulatory standards, and the ELISA method is the most quantifiable and easiest assay to validate.

The new AMS Biotechnology (Abingdon, United Kingdom) pharmacodynamic HT gamma-H2AX assay measures gamma-H2AX levels in cellular extracts and phosphorylation of H2AX in response to therapeutic intervention. This assay documents differences in gamma-H2AX levels in human peripheral blood mononuclear cells, cultured cells, tissue biopsies, and is expected to be useful in future clinical trials providing one of many needed tools to enable hypothesis-driven preclinical drug design strategies.

The ELISA test utilizes immobilized gamma-H2AX antibodies in the wells of a 96-well plate that capture gamma-H2AX from sample lysates. Incubation with a H2AX detecting antibody, followed by addition of a goat anti-mouse HRP (horseradish peroxidase) conjugate and a chemiluminescent HRP substrate yields relative light units (RLU) that directly correlate with the amount of gamma-H2AX in the sample.

Related Links:

AMS Biotechnology


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The real-time multiplex PCR test is set to revolutionize early sepsis detection (Photo courtesy of Shutterstock)

1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens

Sepsis contributes to one in every three hospital deaths in the US, and globally, septic shock carries a mortality rate of 30-40%. Diagnosing sepsis early is challenging due to its non-specific symptoms... Read more

Pathology

view channel
Image: The QIAseq xHYB Mycobacterium tuberculosis Panel uses next-generation sequencing (Photo courtesy of 123RF)

New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance

Tuberculosis (TB), the leading cause of death from an infectious disease globally, is a contagious bacterial infection that primarily spreads through the coughing of patients with active pulmonary TB.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.